Literature DB >> 29180804

Hypertension prevalence, awareness, treatment, and control in northeast China: a population-based cross-sectional survey.

Fu-Liang Zhang1, Zhen-Ni Guo2, Ying-Qi Xing2, Yan-Hua Wu3, Hao-Yuan Liu1, Yi Yang4,5.   

Abstract

Hypertension has been recognized as a major risk factor for cardiovascular disease. We aimed to analyze the current prevalence, awareness, treatment, and control of hypertension in northeast China. This cross-sectional survey adopted the multistage stratified random cluster sampling method to obtain a representative sample of adults aged 40 years or older in the general population of northeast China. Hypertension was defined as a systolic blood pressure (SBP) ≥ 140 mm Hg, or diastolic blood pressure (DBP) ≥ 90 mm Hg, or self-reported use of antihypertensive medications in the last 2 weeks irrespective of BP. Altogether 4052 participants were included with weighted prevalence of hypertension of 57.3%. Among them, 47.4% were aware of their condition; 78.8% took antihypertensive medication, but only 10.2% had their blood pressure controlled. Individuals who were overweight/obesity, with dyslipidemia, or diabetes were at a higher risk of hypertension; these people also more likely to be aware of their condition. Subjects with a personal history of stroke were more inclined to receive antihypertensive medication, but that did not necessarily translate to well-controlled hypertension. Moreover, dyslipidemia (OR = 0.600; 95% CI: 0.375, 0.960) were associated with poor hypertension control. Subjects using combination of antihypertensive medications (OR = 2.924; 95% CI: 1.606, 5.325) or with a family history of coronary heart disease were more likely to have their blood pressure controlled. Our study identified a high prevalence of hypertension in northeast China. Although awareness and treatment rates improved over the last decade, the control rate remained disproportionately and unacceptably low.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29180804     DOI: 10.1038/s41371-017-0003-4

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  35 in total

1.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

2.  Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries.

Authors:  Clara K Chow; Koon K Teo; Sumathy Rangarajan; Shofiqul Islam; Rajeev Gupta; Alvaro Avezum; Ahmad Bahonar; Jephat Chifamba; Gilles Dagenais; Rafael Diaz; Khawar Kazmi; Fernando Lanas; Li Wei; Patricio Lopez-Jaramillo; Lu Fanghong; Noor Hassim Ismail; Thandi Puoane; Annika Rosengren; Andrzej Szuba; Ahmet Temizhan; Andy Wielgosz; Rita Yusuf; Afzalhussein Yusufali; Martin McKee; Lisheng Liu; Prem Mony; Salim Yusuf
Journal:  JAMA       Date:  2013-09-04       Impact factor: 56.272

3.  Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010.

Authors:  Gonghuan Yang; Yu Wang; Yixin Zeng; George F Gao; Xiaofeng Liang; Maigeng Zhou; Xia Wan; Shicheng Yu; Yuhong Jiang; Mohsen Naghavi; Theo Vos; Haidong Wang; Alan D Lopez; Christopher J L Murray
Journal:  Lancet       Date:  2013-06-08       Impact factor: 79.321

4.  The Burden of Hypertension and Associated Risk for Cardiovascular Mortality in China.

Authors:  Sarah Lewington; Ben Lacey; Robert Clarke; Yu Guo; Xiang Ling Kong; Ling Yang; Yiping Chen; Zheng Bian; Junshi Chen; Jinhuai Meng; Youping Xiong; Tianyou He; Zengchang Pang; Shuo Zhang; Rory Collins; Richard Peto; Liming Li; Zhengming Chen
Journal:  JAMA Intern Med       Date:  2016-04       Impact factor: 21.873

5.  Prevalence, Awareness, Treatment, and Control of Hypertension in the Southern Cone of Latin America.

Authors:  Adolfo L Rubinstein; Vilma E Irazola; Matias Calandrelli; Chung-Shiuan Chen; Laura Gutierrez; Fernando Lanas; Jose A Manfredi; Nora Mores; Rosana Poggio; Jacqueline Ponzo; Pamela Seron; Lydia A Bazzano; Jiang He
Journal:  Am J Hypertens       Date:  2016-12-01       Impact factor: 2.689

6.  Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey.

Authors:  Jinwei Wang; Luxia Zhang; Fang Wang; Lisheng Liu; Haiyan Wang
Journal:  Am J Hypertens       Date:  2014-04-03       Impact factor: 2.689

7.  Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010.

Authors:  Fangjian Guo; Di He; Wei Zhang; R Grace Walton
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

8.  Geographic Distributions in Hypertension Diagnosis, Measurement, Prevalence, Awareness, Treatment and Control Rates among Middle-aged and Older Adults in China.

Authors:  Minghui Yin; Balekouzou Augustin; Zhen Fu; Mingming Yan; Adan Fu; Ping Yin
Journal:  Sci Rep       Date:  2016-11-14       Impact factor: 4.379

9.  The ecology of medical care in Beijing.

Authors:  Shuang Shao; Feifei Zhao; Jing Wang; Lei Feng; Xiaoqin Lu; Juan Du; Yuxiang Yan; Chao Wang; Yinghong Fu; Jingjing Wu; Xinwei Yu; Kaykeng Khoo; Youxin Wang; Wei Wang
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

10.  Traditional Chinese medicine and new concepts of predictive, preventive and personalized medicine in diagnosis and treatment of suboptimal health.

Authors:  Wei Wang; Alyce Russell; Yuxiang Yan
Journal:  EPMA J       Date:  2014-02-13       Impact factor: 6.543

View more
  9 in total

1.  Disability Status and Its Influencing Factors Among Stroke Patients in Northeast China: A 3-Year Follow-Up Study.

Authors:  Yumei Lv; Qiuxue Sun; Juan Li; Wenyue Zhang; Yudi He; Yuqiu Zhou
Journal:  Neuropsychiatr Dis Treat       Date:  2021-08-07       Impact factor: 2.570

2.  Clinical Characteristics and Prognosis of Young Patients with Coronary Heart Disease.

Authors:  Ruyi Zheng; Yan Liu; Zirui Hao; Huocheng Liao; Chun Xiao
Journal:  Med Sci Monit       Date:  2020-07-01

3.  Prevalence, awareness, treatment, and control of hypertension and their determinants: Results from the first cohort of non-communicable diseases in a Kurdish settlement.

Authors:  Fatemeh Rajati; Behrooz Hamzeh; Yahya Pasdar; Roya Safari; Mehdi Moradinazar; Ebrahim Shakiba; Shahrzad Bazargan-Hejazi; Hossein Karim; Farid Najafi
Journal:  Sci Rep       Date:  2019-08-27       Impact factor: 4.379

4.  Urban-Rural disparities in status of hypertension in northeast China: a population-based study, 2017-2019.

Authors:  Liying Xing; Li Jing; Yuanmeng Tian; Min Lin; Zhi Du; Han Yan; Guocheng Ren; Yingna Dong; Qun Sun; Shuang Liu
Journal:  Clin Epidemiol       Date:  2019-09-03       Impact factor: 4.790

5.  The urban-rural disparity in the prevalence and risk factors of hypertension among the elderly in China-a cross-sectional study.

Authors:  Hongxun Song; Da Feng; Ruoxi Wang; Jian Yang; Yuanqing Li; Junliang Gao; Zi Wang; Ziqi Yan; Chengxu Long; Jiawei Zhou; Zhanchun Feng
Journal:  PeerJ       Date:  2019-11-07       Impact factor: 2.984

6.  Epidemiological status quo of hypertension in elderly population in Changchun, China: a cross-sectional study.

Authors:  Yaxuan Ren; Jikang Shi; Yichun Qiao; Yulu Gu; Yong Li; Yunkai Liu; Yi Cheng; Yawen Liu
Journal:  BMJ Open       Date:  2022-03-30       Impact factor: 2.692

7.  Association of AGTR1 A1166C and CYP2C9∗3 Gene Polymorphisms with the Antihypertensive Effect of Valsartan.

Authors:  Yi Liu; Xiaomu Kong; Yongwei Jiang; Meimei Zhao; Peng Gao; Xiao Cong; Yongtong Cao; Liang Ma
Journal:  Int J Hypertens       Date:  2022-03-19       Impact factor: 2.420

8.  The effects of the interaction between BMI and dyslipidemia on hypertension in adults.

Authors:  Na Tang; Jian Ma; Rongqin Tao; Zhijun Chen; Yide Yang; Quanyuan He; Yuan Lv; Zelong Lan; Junhua Zhou
Journal:  Sci Rep       Date:  2022-01-18       Impact factor: 4.379

9.  A phase 3 double-blind randomized (CONSORT-compliant) study of azilsartan medoxomil compared to valsartan in Chinese patients with essential hypertension.

Authors:  Jiahui Wu; Xin Du; Qiang Lv; Zhanquan Li; Zeqi Zheng; Yong Xia; Chengchun Tang; Zhuhua Yao; Jun Zhang; Mingzhi Long; Michie Hisada; Jingtao Wu; Wei Zhou; Changsheng Ma
Journal:  Medicine (Baltimore)       Date:  2020-08-07       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.